## CENTER FOR DRUG EVALUATION AND RESEARCH

# APPLICATION NUMBER: 22-160

## **CHEMISTRY REVIEW(S)**

## Memorandum

To:	Division of Drug Oncology Products (DDOP)
Through:	Sarah C. Pope, Ph.D., Haripada Sarker, Ph.D.
From:	Josephine Jee, Chemistry Reviewer
Date:	5/14/2009
Re:	NDA 22-160/0015 – Oxaliplatin Injection - 505(b)(2)

Teva submitted the referenced submission dated 20-MAR-2009 to respond to the Agency's Action (Complete Response) Letter dated 02-MAR-2009. The following Pharmacology/Toxicology deficiency was specified in the 02-MAR-2009 letter:

Your proposed acceptance criteria for <sup>(b) (4)</sup> (Impurity A) and the <sup>(b) (4)</sup> <sup>(b) (4)</sup> (Impurity B) currently exceed ICH Q3B(R2) for Oxaliplatin Injection drug product. The proposed acceptance criteria for these impurities must be lowered to meet the current ICH Q3B (R2) guidance. If these impurity specifications exceed the qualification limits, the impurities will need to be qualified preclinically or justifications for their levels should be provided based on appropriate literature citations.

In the current submission, Teva proposes to lower the release and stability acceptance criteria for Impurity A and Impurity B to meet the current ICH Q3B (R2) criteria. The proposed specifications are as follows:

Impurity A NMT <sup>(b) (4)</sup> Impurity B NMT <sup>(b) (4)</sup>

Based on the previous stability data package and the new proposals for acceptance criteria, the Agency can now grant a 12-month expiration dating period for the drug product (Oxaliplatin Injection). This expiration dating period is consistent with the observed levels for Impurity A and Impurity B, which both occur at levels o (b) (4) at the 12-month time point under long term conditions (25°C/60% RH). These levels exceed the proposed specifications at the (b) (4) time point under the same conditions. Refer to the previous Chemistry Review by Josephine Jee, dated 24-FEB-2009 for additional information.

The carton and vial labels are found adequate by CMC and DMEPA. Refer to the 24-FEB-2009 Chemistry Review for additional information.

2

e

Based on the provided data at 25°C/60% RH of Oxaliplatin Injection, an expiration dating period of 12 months is the maximum that can be granted.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Josephine Jee 5/14/2009 11:12:54 AM CHEMIST

\_\_\_\_\_

Sarah Pope 5/14/2009 11:43:51 AM CHEMIST

### OFFICIAL MEMORANDUM

To: NDA 22-160

From: Terrance Ocheltree, Ph.D., R.Ph. acting for Sarah C. Pope, Ph.D.

CC: Sarah Pope, Ph.D., Haripada Sarker, Ph.D., Josephine Jee, Amy Tilley, Robert Justice, M.D.

Re: NDA 22-160

Date: 02-MAR-2009

This memorandum serves to update the Chemistry, Manufacturing and Controls (CMC) Review dated 24-FEB-2009. At the time of this review, an official consult review from DMEPA had not yet been received with respect to the container/carton labeling. All other CMC issues were resolved, and there were no additional CMC deficiencies noted.

The requested DMEPA consult review was finalized on 25-FEB-2009. The review contained several recommendations regarding to the container/carton labeling. Two of these recommendations were already covered as part of the previous CMC review. These duplicate recommendations included the font size of the dosage form, and a language revision to the dilution statement included in the container/carton labeling. These issues have already been resolved and reviewed as part of the CMC review and therefore, they were not re-conveyed to the Applicant.

The remaining recommendations received from DMEPA were conveyed to the Applicant on 26-FEB-2009, and the Applicant submitted acceptable container/carton labeling that incorporated these revisions on 27-FEB-2009. There are no other outstanding CMC deficiencies for this NDA.

All CMC deficiencies have been resolved for NDA 22-160, and approval is recommended from a CMC perspective.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Terrance Ocheltree 3/2/2009 02:06:38 PM CHEMIST

## CMC REVIEW OF NDA 22-160 Amendments (25-JUN-2008 & 29-AUG-2008)

## **REVIEW # 1**

## OXALIPLATIN INJECTION, 5 MG/ML 50 mg/10 mL and 100 mg/20 mL

## JOSEPHINE M. JEE CMC REVIEWER

## OFFICE OF NEW DRUG QUALITY ASSESSMENT DIVISION OF PREMARKETING ASSESSMENT AND MANUFACTURING SCIENCE (BRANCH V)

## FOR THE DIVISION OF DRUG ONCOLOGY PRODUCTS (HFD-150)

Nide



NDA 22-160

Executive Summary Section OXALIPLATIN INJECTION (5 mg/mL)

Page 2 of 43 Pages

### **Table of Contents**

Ta	ble of Contents	2
Ch	emistry Review Data Sheet	3
Th	e Executive Summary	7
I.	Recommendations	7
	A. Recommendation and Conclusion on Approvability	7
	B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable	7
II.	Summary of Chemistry Assessments	7
	A. Description of the Drug Product(s) and Drug Substance(s)	7
	B. Description of How the Drug Product is Intended to be Used	9
	C. Basis for Approvability or Not-Approval Recommendation	9
III.	Administrative	9
	A. Reviewer's Signature	10
	B. Endorsement Block	10
	C. CC Block	10
Ch	emistry Assessment	11
I.	Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body Of Data	11
	S DRUG SUBSTANCE [Name, Manufacturer]	11
	P DRUG PRODUCT [Name, Dosage form]	20
	A APPENDICES	40
	R REGIONAL INFORMATION	40
II.	Review Of Common Technical Document-Quality (Ctd-Q) Module 1	40
	A. Labeling & Package Insert	40
	B. Environmental Assessment Or Claim Of Categorical Exclusion	43
III.	List Of Deficiencies To Be Communicated	43

NDA 22-160

Executive Summary Section OXALIPLATIN INJECTION (5 mg/mL)

Page 3 of 43 Pages

**Chemistry Review Data Sheet** 

- 1. NDA 22-160 Amendment
- 2. REVIEW: #1
- 3. REVIEW DATE: 24-FEB-2009
- 4. REVIEWER: Josephine M. Jee
- 5. PREVIOUS DOCUMENTS:

<u>Previous Documents</u>	Document Date
Review #1	09-FEB-2007
Oxaliplatin	
NDA 21-801 - (Rolling Submission - CMC)	09-FEB-2007
Amendment	01-MAY-2007
Amendment	04-MAY-2007
Amendment	11-MAY-2007
Amendment	23-MAY-2007
Amendment	17-SEPT-2007

### 6. SUBMISSION(S) BEING REVIEWED:

### Submission(s) Reviewed

NDA 22-160 Amendment/ Sequence 0010 – Complete Response to AP letter and Additional Changes

NDA 22-160/Sequence 006 (Intent to respond to Deficiencies) NDA 22-160/Sequence 009 (Response to CMC deficiencies) NDA 22-160/Sequence 010 (Complete Response to Approvable Letter and Additional Changes)

### 7. NAME & ADDRESS OF APPLICANT:

#### Name:

Teva Parenteral Medicines, Inc.

#### Address:

19 Hughes Irvine, CA 92618-1902

8. DRUG PRODUCT NAME/CODE/TYPE:

### Oxaliplatin

a) Proprietary Name:

None Proposed

- b) Non-Proprietary Name (USAN): International Nonproprietary Name (INN):
- c) Code Name/# (ONDC only): Internal Codes:

Oxaliplatin Oxaliplatin None provided. None provided.

### Document Date

29-AUG-2008 02-SEP-2008 – Stamped Date 14-DEC-2007 25-JUN-2008 29-AUG-2008

**Executive Summary Section** OXALIPLATIN INJECTION (5 mg/mL)

Page 4 of 43 Pages

d) CAS Registry Number:

e) Laboratory Codes:

f) Chemical Name (IUPAC):

Alternative names:

None provided. None provided. SP-4-2)-[(1R,2R)-Cyclohexane-1,2-diamine- $\kappa N$ ,  $\kappa N'$ ] [ethanedioato(2-)- $\kappa O1, \kappa O2$ ]platinum None provided.

g) Chem. Type/Submission Priority (ONDC only):

Chem. Type:

Submission Priority:

9. LEGAL BASIS FOR SUBMISSION:

10. PHARMACOL. CATEGORY:

11. DOSAGE FORM:

12. STRENGTH/POTENCY:

13. ROUTE OF ADMINISTRATION:

14. Rx/OTC DISPENSED: OTC X Rx

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM): N/A

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

(SP-4-2)-[(1R,2R)-Cyclohexane-1,2-diamine- $\kappa N$ ,  $\kappa N'$ ] [ethanedioato(2-)- $\kappa O1$ , $\kappa O2$ ]platinum

Molecular Formula: C<sub>8</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>Pt

Molecular Weight: 397.3

505(b)(2) S

505(b)(2) - Reference: Eloxatin® (oxaliplatin Injection), approved under NDA 21-759 (Lyophilized form) and NDA 21-492 (Solution form)

Treatment of Advanced Colorectal Cancer Injection 5 mg/mL 10 mL (50mg/10 mL), and 20 mL (100 mg/20 ml) vials Intravenously

NDA 22-160



NDA 22-160

Executive Summary Section OXALIPLATIN INJECTION (5 mg/mL)

Page 5 of 43 Pages

- 17. RELATED/SUPPORTING DOCUMENTS:
- A. DMFs:

DMF #	T Y P E	HOLD ER	ITEM REFEREN CED	C O D E 1	STA TUS 2	DATE REVIEW COMPLE TED	COMME NTS
DMF 19559	II	Sicor de México, S.A. de C.V.	Oxaliplatin DS	1	Adeq uate	20-FEB- 2009	Reviewed by J.Jee
(b)	(4) III		(b) (4	3	Adequate	22-APR- 2002	Review conducted by Yvonne Yang, Ph.D.
	111			3	Adequate	19-APR- 2002	Review conducted by Yvonne Yang, Ph.D.
L	III			3	Adequate	10-OCT-2002	Review conducted by Elsbeth Chikhale, Ph.D.

<sup>1</sup> Action codes for DMF Table:

1 - DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2-Type 1 DMF

3 - Reviewed previously and no revision since last review

4 - Sufficient information in application

5 -Authority to reference not granted

6 – DMF not available

7 – Other (explain under "Comments")

<sup>2</sup> Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

### **Other Documents:**

DOCUMENT		APPLICATION NUMBER	DESCRIPTION
IND		None	

### 18. CONSULTS/CMC-RELATED REVIEWS:

CONSULTS	SUBJECT	DATE FORWARDED	STATUS/ REVIEWER	COMMENTS
Biometrics	N/A			
EES	Site inspections	15-DEC-2008	S. Adams	Overall acceptable recommendation received on 05-FEB-2009.
Pharm/Tox	Drug substance, drug product impurity	09-FEB-2007	Dr. M. Brower	Satisfactory on 05-FEB-2009



## **CHEMISTRY REVIEW**

## Executive Summary Section

NDA 22	-160 OXA	LIPLATIN INJECTIO	•	Page 6 of 43 Pages
	qualification (organic and inorganic)			
Biopharm	N/A			
ODS/DMEPA	Carton, Container, and Package Insert	21-JAN-2009	Dr. Raichell Brown	Met w/ Drs. Todd Bridges, Raichell Brown, and Hari Sarker and J. Jee – All agreed with comments. Final review still pending as of 24-FEB- 2009.
Methods Validation	To be submitted post-approval			
EA	N/A	N/A	J.Jee	Categorical exclusion granted (see attached review).
Microbiology	Consulted to the Office of Microbiology	01-MAR-2007	Dr. Bryan Riley	Recommended Approval on 04-DEC-2007.



NDA 22-160

Executive Summary Section OXALIPLATIN INJECTION (5 mg/mL)

Page 7 of 43 Pages

## The Chemistry Review for NDA 22-160

### The Executive Summary

### I. Recommendations

### A. Recommendation and Conclusion on Approvability

From a Chemistry, Manufacturing and Controls standpoint, this New Drug Application is recommended for approval pending acceptable submission of acceptable carton and container labeling. Also note that the review from DMEPA, OSE is still pending. On 24-FEB-2009, applicant agreed to have an <sup>(b) (4)</sup> expiration date for the Oxaliplating Injection as supported by their updated stability data and they have provided updated container/carton labeling. The package insert was found acceptable on 17-FEB-2009. Microbiology review recommended approval on 04-DEC-2007. The Office of Compliance recommended an overall acceptable on 05-FEB-2009. The responses to our comments for DMF 19,559 (Oxaliplatin, Sicor de Mexico) were determined to be acceptable on 20-FEB-2009.

SICOR Pharmaceuticals, Inc. requests a waiver for evidence of bioavailability/bioequivalence in accordance with 21 CFR §320.22(b)(1). SICOR's drug product meets the required criteria:

- 1) Oxaliplatin Injection, 5 mg/mL is a parenteral drug product intended for administration by intravenous infusion.
- 2) SICOR's proposed drug product has the same active pharmaceutical moiety, dosage form, strength, route of administration, and conditions of use as Sanofi Aventis' Eloxatin® Injection (oxaliplatin injection), previously approved under NDA No. 21-759.
- 3) The only difference between the proposed drug product and Eloxatin® Injection is that SICOR's product contains lactose as an excipient. However, Sanofi Aventis' Eloxatin® for Injection also contained lactose.

From a CMC standpoint, waiver for evidence of bioequivalence is recommended. Also refer to the Clinical Pharmacology review dated 30-NOV-2007 for further information.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable There are no Phase 4 CMC commitments.

### II. Summary of Chemistry Assessments

### A. Description of the Drug Product(s) and Drug Substance(s) Drug Product:

Oxaliplatin injection is formulated as 5 mg/mL sterile, preservative-free aqueous solution. This concentrate solution is further diluted in an infusion solution of 250 -500 mL of 5% Dextrose Injection, USP for intravenous administration. The concentrate formulation includes lactose monohydrate.

The concentrate solution is manufactured by

(b) (4)

NDA 22-160

Executive Summary Section OXALIPLATIN INJECTION (5 mg/mL)

Page 8 of 43 Pages (b) (4)

The NDA submission included a batch analysis for Sanofi Aventis' Eloxatin® Injection (oxaliplatin injection) for the purpose of comparison. The test results obtained from Eloxatin Injection are very similar to the ones obtained for batches manufactured by SICOR.

The applicant proposed Pharmachemie B.V., Swensweg 5, 2031GA Haarlem, The Netherland as the drug product manufacturing site. An acceptable EES recommendation by the Office of Compliance was received on 05-FEB-2009.

The applicant provided long term  $(25^{\circ}C \pm 2^{\circ}C/60\% \text{ RH} \pm 5\% \text{ RH}, 24 \text{ months})$  stability data for three commercial-scale batches of oxaliplatin Injection, 5 mg/mL (50 mg /10 mL Vial) and three batches of oxaliplatin Injection, 5 mg/mL (100 mg /20 mL Vial) stored in an inverted and upright positions. Photostability conditions were studied using one of the primary stability batches and found that the drug product is photostable. In addition, the applicant provided accelerated (40°C  $\pm 2^{\circ}C/75\%$  RH  $\pm 5\%$  RH, 6 months) stability data in all batches submitted. All three primary stability batches were manufactured using the proposed commercial process. All batch analysis and stability data were all within the proposed drug product specification.

The applicant proposed a <sup>(b) (4)</sup> expiration dating period for the drug product, when stored under room temperature condition  $(25^{\circ}C \pm 2^{\circ}C/60\% \text{ RH} \pm 5\% \text{ RH})$ , they submitted up to 24 months of long term and 6 months at accelerated storage conditions. However, the results of the long term stability study in three of the batches submitted do not meet the drug product specification for Total of Impurities after 18 months. The same three batches do not meet Impurity C specification after 2 months and Total of Impurities after three months at accelerated conditions. Based on these results, an <sup>(b) (4)</sup> expiration dating is recommended. The applicant proposed to have acceptance criteria for related substances at release different from those for the shelf life or stability specification. After discussion with the Pharmacology Team, the related substances should be maintained at the following levels: Impurity A: NMT <sup>(b) (4)</sup> and Total of Impurities: NMT <sup>(b) (4)</sup>.

On 23-FEB-2009, the following deficiency was emailed to Teva:

1. We recommend that you maintain the currently-proposed drug product release specifications for related substances (Impurity A: NMT <sup>(b) (4)</sup> Impurity B: <sup>(b) (4)</sup>, Impurity C: <sup>(b) (4)</sup> Any Other Related Substance: NMT <sup>(b) (4)</sup>, and Total of Impurities: NMT <sup>(b) (4)</sup> to be the same as those proposed in the drug product shelf life specifications.

In a 24-FEB-2009 teleconference and subsequent official submission, Teva agreed to reduce their proposed <sup>(b) (4)</sup> expiration dating to <sup>(b) (4)</sup> In addition, Teva have provided the requested changes for the carton and container labels. A final review is still pending from DMEPA, OSE.

### Drug Substance:

Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2 diamino-cyclohexane(DACH) and with an oxalate ligand as a leaving group. It is a white or almost white crystalline powder. Oxaliplatin is slightly soluble in water, very slightly soluble in methanol, and practically insoluble in ethanol and acetone. There is no polymorphism. The Differential Scanning Calorimetry shows an exotherm at about 300°C followed by decomposition.



Executive Summary Section

NDA 22-160

160 OXALIPLATIN INJECTION (5 mg/mL) Page 9 of 43 Pages The control of starting materials and the synthesis are described in DMF 19,559, SICOR de Mexico.

The drug substance is tested by SICOR for description, identification (IR and HPLC), appearance of solution (clarity and color) <USP and EP>, acidity <USP and EP>, specific rotation (USP <781>, assay (HPLC), related substances (HPLC), residual solvents

, bacterial endotoxins (USP <85>), microbial purity (USP <61>),  $^{(b)}$  (4) r <USP and EP>.

Oxaliplatin was accepted as a United States Adopted Name (USAN) in 1998.

SICOR submitted batch analyses for eight (8) batches of oxaliplatin drug substance, but no stability data was provided in NDA 22-160. Since, the DMF Holder is one of their subsidiaries, they rely on the DMF Holder stability data. See DMF 19559 Reviews dated on 30-OCT-2007 and 20-FEB-2009 for stability data.

### Description of How the Drug Product is Intended to be Used

Oxaliplatin is indicated for the adjuvant treatment of stage III colon cancer patients and treatment of advanced colorectal cancer. The recommended dose of Oxaliplatin is  $85 \text{ mg/m}^2$  intravenous (IV) infusion in 250 - 500 mL 5% Dextrose in combination with infusional 5-fluorouracil (5-FU) and leucovorin (LV) every two (2) weeks.

After Oxaliplatin Injection dilution with 250-500 mL of 5% Dextrose Injection, USP, the shelf life is 6 hours at room temperature [20-25°C (68-77°F)] or up to 24 hours under refrigeration [2-8°C (36-46°F)]. Oxaliplatin is incompatible in solution with alkaline medications or media (such as basic solutions of 5-FU) and must not be mixed with these or administered simultaneously through the same infusion line. The infusion line should be flushed with D5W prior to administration of any concomitant medication. Oxaliplatin is not light sensitive.

The marketed drug product would be supplied in clear, glass, single-use vials with gray elastomeric stoppers and aluminum flip-off seals containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free aqueous solution at a concentation of 5 mg/mL. Lactose monohydrate is present as an inactive ingredient at 450 mg and 900 mg in the 50 mg and 100 mg dosage strengths, respectively.

The NDC 1234-5678-90: 50 mg single-use vial with flip-off seal individually packaged in a carton. The NDC 1234-5678-90: 100 mg single-use vial with flip-off seal individually packaged in a carton. The recommended storage condition is at  $25^{\circ}$ C ( $77^{\circ}$ F); excursions permitted to  $15-30^{\circ}$ C ( $59-86^{\circ}$ F) [see USP controlled room temperature].

The recommended handling and disposal statement is included in detail together with the applicable references.

### C. Basis for Approvability or Not-Approval Recommendation

This NDA is recommended for Approval from a Chemistry, Manufacturing, and Controls standpoint pending on satisfactory carton and container labels. The stability updates (SICOR) for the drug product are acceptable in support of an <sup>(b) (4)</sup> expiration dating period, the responses to our comments to DMF 19,559, SICOR de Mexico, S.A. de C.V. are satisfactory, the microbiology consult recommended approval on 04-DEC-2007, and an overall acceptable recommendation was issued by the Office of Compliance on 05-FEB-2009.

B.



Executive Summary Section OXALIPLATIN INJECTION (5 mg/mL)

Page 10 of 43 Pages

NDA 22-160 III. Administrative

This NDA was submitted electronically as a 505(b)(2) application. A Quality Overall Summary is included in the application. Although, Sanofi Aventis' Eloxatin® for Injection was withdrawn from the US market, a <u>Citizen's Petition</u> was filed requesting that the Commissioner make a determination that this product was not voluntarily withdrawn from sale due to safety or effectiveness reasons (refer to docket 2006P-0291/CP1).

SICOR Pharmaceuticals, Inc. requests a waiver for evidence of bioavailability/bioequivalence in accordance with 21 CFR §320.22(b)(1). The drug product met all the criteria under 21 CFR §320.22(b)(1); therefore, the waiver is recommended from a CMC standpoint.

### A. Reviewer's Signature

See electronic signatures in Division File System (DFS).

### B. Endorsement Block

See electronic signatures in DFS

C. CC Block

See DFS

33 Page(s) has been Withheld in Full immediately following this page as B4 (CCI/TS)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. 

/s/ ------Josephine Jee 2/24/2009 05:13:31 PM CHEMIST

----

Haripada Sarker 2/24/2009 05:15:22 PM CHEMIST

Sarah Pope 2/25/2009 11:15:48 AM CHEMIST

### **DMF REVIEW**

Title: Oxaliplatin DMF No. 19,559

### 1. CHEM REVIEW AMENDMENT No. 1

#### 2. REVIEW DATE: 20-FEB-2009

### **3. ITEM REVIEWED**

A. IDENTIFICATION USAN: rINN:

Oxaliplatin

Chemical Name:

(SP-4-2)-( (1 R,2R)-Cyclohexane-1 ,2-diamine-κN, κN') (ethanedioato (2-)- $\kappa O^1$ ,  $\kappa O^2$ ) platinum

Molecular Formula: C<sub>8</sub> H<sub>14</sub>N<sub>2</sub>0<sub>4</sub>Pt

Trade Name:

N/A

CAS Number:

61825-94-3

Other Names: Chemical Name:

None provided.

NH<sub>2</sub> ŇH-

Molecular Weight: 397.3

**4. DOCUMENTS** 

**Type of Document Date of Document** Location Original 07-AUG-2006 Vol. 1.1, Vol., 1.2, (Reviewed on 10/30/07) Amend. 20-FEB-2008 Vol. 1.3 Amend. 31-AUG-2008 Vol. 2.1

## 5. NAME & ADDRESS OF DMF HOLDER REPRESENTATIVE(S):

Name (Holder): TEVA Pharmaceutical - API Division (Sicor de México, S.A. de C.V.) Address: 5 Bazel St. P.O. B. 3190 Petah Tiqva 49131, Israel

Responsible Agent: Hana Shahar, Regulatory Affairs Manager **TEVA Group**, API Division

REPRESENTATIVE or U.S. AGENT: NAME: N/A PHONE: N/A

**CONTACT PERSON NAME:** Hana Shahar, Regulatory Affairs Manager Teva Pharmaceuticals - API Division **Teva Pharamceuticals** 5 Bazel St,, P.O.B. 3190 Petah Tiqva 49131, israel

### 6. DMF REFERENCED FOR: NDA: PRIMARY DMF: APPLICANT NAME: LOA DATE:

22-160 Yes Teva Parenteral Medicines, Inc. 14-AUG-2006

DRUG PRODUCT NAME:	Oxaliplatin
DOSAGE FORM:	Injection
CODE:	-
STRENGTH:	5 mg/mL (50 mg/10 mL and 100 mg/ 20 mL)
ROUTE OF ADMINISTRATION:	Intravenous by Infusion

7. SUPPORTING DOCUMENTS: NDA 22-160

### 8. CURRENT STATUS OF DMF:

DATE OF LAST UPDATE OF DMF: 07-AUG-2006 (Original submission) Date of most recent List of Companies for which LOA's Have Been Provided: August 7, 2007

### 9. CONSULTS: None

**10.COMMENTS:** DMF 19,559 Amendments submitted on 20-FEB-2008 and 31-AUG-2008 by Sicor de Mexico in response to comments submitted on Nov 7, 2007 have provided adequate information to support oxaliplatin API to be used for NDA 22-160.

### 11. CONCLUSIONS: Adequate.

cc: Orig. DMF 19,559 DDOP DMF File DDOP/J.Jee/20-FEB-2008 DDOP/H. Sarker DDOP/S. Pope DDOP/A.Tilley Doc: DMF 19559 Oxaliplatin.AMD

> Josephine Jee Review Chemist, CMC Branch V (Pre-Marketing) Division of Pre-Market Assessment III & Manufacturing Science, ONDQA

Sarah C. Pope, Ph. D. Chief, CMC Branch V (Pre-Marketing) Division of Pre-Market Assessment III & Manufacturing Science, ONDQA.

11 Page(s) has been Withheld in Full immediately following this page as B4 (CCI/TS)

Linked Applications

Sponsor Name

-----

Drug Name / Subject

MF 19559

SICOR DE MEXICO SA DE CV OXALIPLATIN AS MANUFACTURED IN ESTADO DE MEXICO, MEXICO.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOSEPHINE M JEE 02/24/2009

SARAH C POPE 02/25/2009 Concur

HARIPADA SARKER 02/25/2009

From: Ravi S. Harapanhalli, Ph.D., Branch Chief, ONDQA Harapanhalli 12/4/07 To: Robert Justice, M.D.

Through: Rik Lostritto M.D.

12/4/07 Subject: NDA 22-160 Oxaliplatin Injection, Applicant: SICOR Pharmaceuticals, Inc. Reference: Impact of Sanofi-Aventis' Citizen Petition and Citizen Petition Supplement for Oxaliplatin on the approval of NDAs

Background:

SICOR's Formulation:

Oxaliplatin Injection, 5 mg/ml contains the same active ingredient in the same concentration as the innovator drug product Eloxatin Injection, 5 mg/ml marketed by Sanofi Aventis. The only difference is that the innovator formulation contains oxaliplatin in water for injection whereas SICOR's formulation contains an additional <sup>(b) (4)</sup> of lactose monohydrate per ml along with 5 mg of oxaliplatin. It should be noted that Sanofi Aventis marketed (NDA 21-492 and 21-759) a lyophilized oxaliplatin formulation containing lactose during 1993 to 2004 and switched the formulation to an aqueous solution as mentioned above.

Impurities of concern:

The following impurities are identified and are described in both NDAs.

Comparative specifications for impurities:

SICOR NDA	Sanofi Aventis
22-068	NDAs 21-492/21-759
	(b

SICOR's Stabilit	y data (	12 Months at room temperature storage):

Impurity	SICOR NDA	10-ml Vials	20-ml Vials
	Specification	25°C/60% RH	25°C/60% RH
			(b)

**Observations and Results:** 

- (<sup>b) (4)</sup> ot found in the RLD is specified a (<sup>b) (4)</sup> n SICOR's NDA and is within the qualification threshold according to ICH Q3B® since the maximum daily dose (MDD) is (<sup>b) (4)</sup>
- Assay range is tighter in SICOR's specifications than it is in the RLD
- Total impurities range in SICOR's NDA may be tightened to NM<sup>(b) (4)</sup> % and SICOR may be asked to submit stability updates if they expect an expiration dating period beyond 12 months.

### Conclusion:

The Sanofi-Aventis petitioned that the Agency require all applicants for approval of generic formulations referencing Eloxatin solution (ANDAs and also 505(b)(2) applications), containing an acid other than oxalic acid or a conjugate base thereof, or solutions containing added sugars such as lactose, to demonstrate through sufficient preclinical and/or clinical testing that any new compound resulting from such formulations do not compromise the safety or efficacy of the drug product. As seen above, SICOR's specifications are within the specification limits for all Pt-containing degradation products listed in Sanofi-Aventis' NDA. These impurities are known and identified impurities described in SICOR's as well as Sanofi-Aventis' NDAs. Also, none of them exceeds the qualification threshold (which is NMT 0.2% in this case). Therefore, from the CMC view point, the approval of SICOR's NDA is not impacted by Sanofi-Aventis' CP.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Ravi Harapanhalli 12/4/2007 04:27:55 PM CHEMIST Impact of Sanofi-Aventis' CP on NDA approval

## **CMC REVIEW OF NDA 22-160**

## REVIEW # 1 OXALIPLATIN INJECTION, 5 MG/ML 50 mg/10 mL and 100 mg/20 mL

## JOSEPHINE M. JEE CMC REVIEWER

## OFFICE OF NEW DRUG QUALITY ASSESSMENT DIVISION OF PREMARKETING ASSESSMENT AND MANUFACTURING SCIENCE (BRANCH V)

## FOR THE DIVISION OF DRUG ONCOLOGY PRODUCTS (HFD-150)

and an loss of the second s

NDA 22-160

Executive Summary Section OXALIPLATIN INJECTION (5 mg/mL)

Page 2 of Pages

Table of Contents

Ta	ble of Contents	2
	iemistry Review Data Sheet	
Th	e Executive Summary	
I.	Recommendations	6
	A. Recommendation and Conclusion on Approvability	6
	B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable	6
II.	Summary of Chemistry Assessments	6
	A. Description of the Drug Product(s) and Drug Substance(s)	6
	B. Description of How the Drug Product is Intended to be Used	7
	C. Basis for Approvability or Not-Approval Recommendation	8
III.	Administrative	8
	A. Reviewer's Signature	8
	B. Endorsement Block	8
	C. CC Block	8
Ch	emistry Assessment	9
I.	Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body Of Data	9
	S DRUG SUBSTANCE [Name, Manufacturer]	9
	P DRUG PRODUCT [Name, Dosage form]	20
	A APPENDICES	56
	R REGIONAL INFORMATION	56
II.	Review Of Common Technical Document-Quality (Ctd-Q) Module 1	57
	A. Labeling & Package Insert	57
	B. Environmental Assessment Or Claim Of Categorical Exclusion	61
III.	List Of Deficiencies To Be Communicated	63

	NDA 22-160	Executive Summary Section OXALIPLATIN INJECTION (5 mg/mL) Chemistry Review Data Sheet	Page 3 of	Pages
1.	NDA	22-160		
2.	REVIEW:	#1		
3.	REVIEW DATE:	05-NOV-2007		
4.	<b>REVIEWER:</b>	Josephine M. Jee		
5.	PREVIOUS DOCUMENTS:			

None

### 6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed
NDA 21-801 - (Rolling Submission - CMC)
Amendment

Document Date
09-FEB-2007
01-MAY-2007
04-MAY-2007
11-MAY-2007
23-MAY-2007
17-SEPT-2007

### 7. NAME & ADDRESS OF APPLICANT:

Name:

Address:

SICOR Pharmaceuticals, Inc.

19 Hughes Irvine, CA 92618-1902

### 8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name:

### None Proposed

Oxaliplatin

Oxaliplatin

- b) Non-Proprietary Name (USAN): International Nonproprietary Name (INN): Oxaliplatin c) Code Name/# (ONDC only):
- Internal Codes:
- d) CAS Registry Number:
- e) Laboratory Codes:
- f) Chemical Name (IUPAC):

Alternative names:

None provided. None provided. None provided. None provided. SP-4-2)-[(1R,2R)-Cyclohexane-1,2-diamine-KN, KN'] [ethanedioato(2-)κ01,κ02]platinum

None provided.

Contraction of the second s	:		CHEMIST	RY R	EVIEV	V		James and a series and
NDA	A 22-160	OX	Executive Su ALIPLATIN INJEC				Page 4 of	Pages
g) Chem. T	ype/Sul	bmission Priority (	(ONDC only):					
•	Chem.	Туре:	• • •	50	05(b)(2)			
•	Submis	sion Priority:		S				
9. LEGAL BASIS FOR SUBMISSION:				In (L	505(b)(2) - Reference: Eloxatin® (oxaliplatin Injection), approved under NDA 21-759 (Lyophilized form) and NDA 21-492 (Solution form)			
10. PHARM	ACOL.	CATEGORY:		Т	reatment of	Advan	ced Colorectal Can	cer
11. DOSAG					jection			
12. STRENG	GTH/PC	DTENCY:		5 mg/mL				
13. ROUTE OF ADMINISTRATION:			<b>10 mL (50mg/10 mL), and 20 mL (100 mg/20 ml) vial</b> Intravenously					
	-4-2)-[(]		ne-1,2-diamine-κλ		•	το(2-)-κι	- - -	WEIGHT:
17. RELATH A. DMFs:		PORTING DOCU				, orgint.		
	Т			C	4		DATE	
DMF	Y	HOLD	ITEM REFEREN	O D			REVIEW	COMME
#	P E	ER	CED		2	5	COMPLE TED	NTS
DMF		Sicor de	Oxaliplatin	1	Inad	<u> </u>	30-OCT-	Reviewed
19559	Î	México, S.A. de C.V.	DS		quat	-	2007	by J.Jee
(b) (4	4) III			(b) (4) 3	Ađe	quate	22-APR-	Reviewed by
	1			1	1.00	7	2002	

.

<sup>1</sup>Action codes for DMF Table:

1 - DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

### **Executive Summary Section** OXALIPLATIN INJECTION (5 mg/mL)

Page 5 of Pages

NDA 22-160 2-Type 1 DMF

3 - Reviewed previously and no revision since last review

4 – Sufficient information in application

5 -Authority to reference not granted

6 – DMF not available

7 – Other (explain under "Comments")

<sup>2</sup>Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

**Other Documents:** 

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
IND	None	

### 18. CONSULTS/CMC-RELATED REVIEWS:

CONSULTS	SUBJECT	DATE FORWARDED	STATUS/ REVIEWER	COMMENTS
Biometrics	N/A			
EES	Site inspections	21-FEB-2007	S.Adams	Acceptable on 27-NOV-2007
Biopharm	N/A			
ODS/DMETS	N/A			Consult pending
Methods Validation	Pharm. Eur. & Proposed USP			No validation is needed
EA	N/A	N/A	J.Jee	Categorical exclusion granted (see attached review).
Microbiology	Consulted to the Office of Microbiology	01-MAR-2007	Dr. S. Langille	Acceptable recommendation provided on 03-DEC-2007.

NDA 22-160

**Executive Summary Section** OXALIPLATIN INJECTION (5 mg/mL)

Page 6 of Pages

### The Chemistry Review for NDA 22-160

### The Executive Summary

#### I. Recommendations

A. **Recommendation and Conclusion on Approvability** 

> The Office of Compliance deemed all facilities acceptable for cGMP Compliance on 27-NOV-2007. The Product Quality Microbiology recommended approval on 03-DEC-2007. However, from a Chemistry, Manufacturing and Controls standpoint, this New Drug Application is approvable, pending the resolution of the CMC issues listed at the end of the review, acceptable responses to our comments for DMF 19,559 (Oxaliplatin, Sicor de Mexico). SICOR Pharmaceuticals, Inc. requests a waiver for evidence of bioavailability/bioequivalence in accordance with 21 CFR §320.22(b)(1). SICOR's drug product meets the required criteria:

- 1) Oxaliplatin Injection, 5 mg/mL is a parenteral drug product intended for administration by intravenous infusion.
- 2) SICOR's proposed drug product has the same active pharmaceutical moiety, dosage form, strength, route of administration, and conditions of use as Sanofi Aventis' Eloxatin® Injection (oxaliplatin injection), previously approved under NDA No. 21-759.
- 3) The only difference between the proposed drug product and Eloxatin® Injection is that SICOR's product contains lactose as an excipient.
- However, Sanofi Aventis' discontinued formulation, Eloxatin® for Injection also contained lactose.

From a CMC standpoint, waiver for evidence of bioequivalence is recommended.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or **Risk Management Steps, if Approvable** There are no Phase 4 CMC commitments.

#### II. **Summary of Chemistry Assessments**

#### Description of the Drug Product(s) and Drug Substance(s) A. **Drug Product:**

Oxaliplatin injection is formulated as 5 mg/mL sterile, preservative-free aqueous solution. This concentrate solution is further diluted in an infusion solution of 250 -500 mL of 5% Dextrose Injection, USP for intravenous administration. The concentrate formulation includes lactose monohydrate.

The concentrate is manufactured by

(b) (4)

Andread and the first states

### Executive Summary Section

NDA 22-160

160 OXALIPLATIN INJECTION (5 mg/mL) Page 7 of Pages (b) (4) The NDA submission included a batch analysis for Sanofi Aventis' Eloxatin® Injection (oxaliplatin injection) for the purpose of comparison. The test results obtained from Eloxatin Injection are very similar to the ones obtained for batches manufactured by SICOR.

The applicant proposed Pharmachemie B.V., Swensweg 5, 2031GA Haarlem, The Netherland as the drug product manufacturing site. An EES recommendation by the Office of Compliance is pending.

The applicant provided long term  $(25^{\circ}C \pm 2^{\circ}C/60\% \text{ RH} \pm 5\% \text{ RH}, 12 \text{ months})$  stability data for three commercial-scale batches of oxaliplatin Injection, 5 mg/mL (50 mg/10 mL Vial) and one batch of oxaliplatin Injection, 5 mg/mL (100 mg/20 mL Vial), and two batches of oxaliplatin Injection, 5 mg/mL (100 mg/20 mL Vial) at  $(25^{\circ}C \pm 2^{\circ}C/60\% \text{ RH} \pm 5\% \text{ RH}, 9 \text{ months})$  when stored in an inverted and upright positions. Photostability conditions were studied using one of the primary stability batches. In addition, the applicant provided accelerated  $(40^{\circ}C \pm 2^{\circ}C/75\% \text{ RH} \pm 5\% \text{ RH}, 6 \text{ months})$  stability data for all submitted batches. All three primary stability batches were manufactured using the proposed commercial process. All batch analysis and stability data were all within the proposed drug product specification.

The applicant proposed (b) (4) expiration dating period for the concentrate, when stored under room temperature conditions (25°C ± 2°C/60% RH ± 5% RH), however, they submitted only up to twelve months of data and are expected to submit additional update.

### Drug Substance:

Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2 diamino-cyclohexane(DACH) and with an oxalate ligand as a leaving group. It is a white or almost white crystalline powder. Oxaliplatin is slightly soluble in water, very slightly soluble in methanol, and practically insoluble in ethanol and acetone. There is no polymorphism. The differential Scanning Calorimetry shows an exotherm at about 300°C followed by decomposition. The control of starting materials and the synthesis are described in DMF 19,559, SICOR de Mexico.

The drug substance is tested by SICOR for description, identification (IR and HPLC), appearance of solution (clarity and color) <USP and EP>, acidity <USP and EP>, specific rotation (USP <781>, assay (HPLC), related substances (HPLC), residual solvents

, bacterial endotoxins (USP <85>), microbial purity (USP <61>), <sup>(b) (4)</sup> <USP and EP>.

Oxaliplatin was accepted as a United States Adopted Name (USAN) in 1998.

SICOR submitted batch analyses for eight (8) batches of oxaliplatin drug substance, but no stability data was provided in NDA 22-160. Since, the DMF Holder is one of their subsidiaries, they rely on the DMF Holder stability data. Up to 12 months of long-term stability data and 6 months of accelerated stability data are submitted for 6 batches of oxaliplatin drug substance by the DMF Holder. The stability data obtained from batches tested by SICOR de Mexico conform with the Oxaliplatin Drug Substance specification.

### B. Description of How the Drug Product is Intended to be Used

Oxaliplatin is indicated for the adjuvant treatment of stage III colon cancer patients and treatment of advanced colorectal cancer. The recommended dose of Oxaliplatin is  $85 \text{ mg/m}^2$  intravenous (IV) infusion in 250 - 500 mL 5% Dextrose in combination with infusional 5-fluorouracil (5-FU) and leucovorin (LV) every two (2) weeks.

### **Executive Summary Section**

#### NDA 22-160

160 OXALIPLATIN INJECTION (5 mg/mL) Page 8 of Pages After Oxaliplatin Injection dilution with 250-500 mL of 5% Dextrose Injection, USP, the shelf life is 6 hours at room temperature [20-25°C (68-77°F)] or up to 24 hours under refrigeration [2-8°C (36-46°F)]. Oxaliplatin is incompatible in solution with alkaline medications or media (such as basic solutions of 5-FU) and must not be mixed with these or administered simultaneously through the same infusion line. The infusion line should be flushed with D5W prior to administration of any concomitant medication. Oxaliplatin is not light sensitive.

The marketed drug product will be supplied in clear, glass, single-use vials with gray elastomeric stoppers and aluminum flip-off seals containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free aqueous solution at a concentration of 5 mg/mL. Lactose monohydrate is present as an inactive ingredient at 450 mg and 900 mg in the 50 mg and 100 mg dosage strengths, respectively.

The NDC 1234-5678-90: 50 mg single-use vial with flip-off seal individually packaged in a carton. The NDC 1234-5678-90: 100 mg single-use vial with flip-off seal individually packaged in a carton. The recommended storage condition is at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP controlled room temperature].

The recommended handling and disposal statement is included in detail together with the applicable references.

### Basis for Approvability or Not-Approval Recommendation

This NDA is approvable from a Chemistry, Manufacturing, and Controls standpoint pending satisfactory responses to the deficiencies in DMF 19,559.

Acceptable cGMP recommendation from the Office of Compliance was dated 27-NOV-2007. Acceptable recommendation from the Product Quality Microbiology on 03-DEC-2007.

### **III.** Administrative

C.

This NDA was submitted electronically as a 505(b)(2) application. A Quality Overall Summary is included in the application. Although, Sanofi Aventis' Eloxatin® for Injection was withdrawn from the US market, a <u>citizen petition</u> has been filed requesting the Commissioner to make a determination that this product was not voluntarily withdrawn from sale due to safety or effectiveness reasons (refer to docket 2006P-0291/CP1).

SICOR Pharmaceuticals, Inc. requests a waiver for evidence of bioavailability/bioequivalence in accordance with 21 CFR §320.22(b)(1). The drug product met all the criteria under 21 CFR §320.22(b)(1); therefore, the waiver is recommended from a CMC standpoint.

### A. Reviewer's Signature

See electronic signatures in Division File System (DFS).

**B.** Endorsement Block

See electronic signatures in DFS

#### C. CC Block

See DFS

62 Page(s) has been Withheld in Full immediately following this page as B4 (CC /TS)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/ Josephine Jee 12/3/2007 03:08:58 PM CHEMIST

Ravi Harapanhalli 12/3/2007 03:12:02 PM CHEMIST AE recommendation

### INITIAL QUALITY ASSESSMENT

### OFFICE OF NEW DRUG QUALITY ASSESSEMNT DIVISION OF PREMARKETING ASSESSMENT AND MANUFACTURING SCIENCE (BRANCH V) CMC REVIEW OF NDA 22-160 FOR THE DIVISION OF ONCOLOGY DRUG PRODUCTS (HFD-150)

OND Division: NDA: Applicant: Assigned Date: Stamp date: PDUFA Date: Proposed Trade Name: Established Name: Laboratory Code: Dosage Form:

Route of Administration:

CMC Reviewer:

ONDQA Fileability: Draft Comments for 74-Day Letter: Division of Drug Oncology Products 22-160 SICOR Pharmaceuticals, Inc. 20-FEB-2007 09-FEB-2007 09-DEC-2007 None proposed. Oxaliplatin Injection None Oxaliplatin Injection, 5 mg/mL in 10 mL (50mg/10 mL), and 20 mL (100 mg/20 ml) vials Intravenously.

Josephine Jee

YES

NO

### Summary, Critical Issues and Comments

#### Summaries A.

### **Background Summary**

NDA 22-160 has been submitted under Section 505(b)(2) for Oxaliplatin Injection, 5 mg/mL, intended for treatment of advanced colorectal cancer. Reference is made to Eloxatin® (oxaliplatin injection), as approved under NDA 21-759 and NDA 21-492. The basis for NDA 22-160 is a formulation revision to the reference listed drug Eloxatin (oxaliplatin injection). The approved and proposed products have the same active ingredient, dosage form, strength, route of administration, and conditions of use as the innovator drug Eloxatin® (oxaliplatin injection). However, the proposed drug product also contains lactose, which was present at the same concentration in Sanofi-Aventis's previously marketed lyophilized dosage form of Eloxatin® (oxaliplatin injection). SICOR's liquid formulation of the drug was developed to match the assay and impurity profiles of the innovator's discontinued lyophilized drug after reconstitution.

A full comparison of SICOR's proposed drug to the innovator's drugs is provided in the NDA.

### **Drug Substance Summary**

Oxaliplatin is a white to almost white crystalline powder, which is slightly soluble in water, very slightly soluble in methanol, and practically insoluble in ethanol. Oxaliplatin thermally decomposes at 300°C, is isomorphic (confirmed by X-ray diffraction), and the specific optical rotation is 74.5° - 78.0°.

The chemical structure of Oxaliplatin is as follows:

397.3

**Chemical Name:** 

 $(SP-4-2)-[(1R,2R)-Cyclohexane-1,2-diamine-\kappa N, \kappa N']$  [ethanedioato(2-)- $\kappa O1,\kappa O2$ ]platinum

**Molecular Formula:** C<sub>8</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>Pt

Molecular Weight:

The Chemistry, Manufacturing and Controls information for oxaliplatin is cross-referenced to DMF 19,559 (Sicor de México, S.A. de C.V). DMF 19,559 was filed with the Agency on 16-JUN-2006.. The active substance will be re-tested at Pharmachemie after (b) (4)

The proposed manufacturing site is listed below:

### Site(s) of Drug Substance Manufacturing:

Sicor de México, S.A. de C.V., Av. San Rafael No. 35 Parque Industrial Lerma Lerma, Estado de México, C.P. 52000 México

### **Drug Product Summary**

The formulation is a sterile, preservative-free solution for parenteral administration via intravenous infusion. Two fill volumes are proposed: a 10-mL (50 mg) fill volume and a 20-mL (100 mg) fill volume. Both vials contain the same 5 mg/mL solution. The drug product also includes the following compendial inactive ingredients: lactose monohydrate and water for injection. (b) (4)

The proposed batch size is

2

### **Composition:**

Component	Unit formula per vial	Unit formula per vial				
	10 mL <sup>1</sup>	-	20 mL <sup>1</sup>			
Drug substance						
Oxaliplatin	50 mg	÷	100 mg			
Excipients						
Lactose monohydrate	450 mg	2	900 mg			
Water for Injection				(b) (		
Primary packaging	_					
Container	Colorless glass vial ( (b) (4)	(b) (4)	Coloriess glass vial (b) (4)	(b) (4)		
	(b) (4)		(b) (4)			
Closure			<u> </u>	(b) (		
Snap-cap	Aluminum seal (b) (b) (4)		Aluminum sea!( (b) (4);			
	1			(b) (4		

### **B. Preliminary Comments and Recommendations**

#### Drug Substance Section

All drug substance information has been cross-referenced to DMF 19,559 (see Letter of Authorization dated 07-AUG-2006).

#### Drug Product Section

The Sponsor has provided three pilot batches for the 10 mL fill volume (two batches (b) (4)) and three batches for the 20 mL fill volume (b) (4)). The proposed commercial batch size is (b) (4) Twelve (12) months of long-term (25°C ± 2°C/60% ± 5% RH) stability data and six (6) months of the corresponding accelerated (40°C ± 2°C/75% ± 5% RH) stability data. The proposed marketed stability protocol are:

Long-term testing conditions

Storage conditions:  $25^{\circ}C \pm 2^{\circ}C/60\%$  RH  $\pm 5\%$  RH. Testing frequency: 0, 3, 6, 9, 12, 18, 24 and 36 months. *Accelerated testing conditions* Storage conditions:  $40^{\circ}C \pm 2^{\circ}C/75\%$  RH  $\pm 5\%$  RH. Testing frequency: 0, 3 and 6 months.

The Sponsor has proposed a  $(b)^{(4)}$  expiration dating period for the drug product, when stored at 25°C ± 2°C/60% RH ± 5% RH.

### C. Critical issues for review and recommendation

#### Drug Substance

a. DMF 19559 was received by the Agency (29-JUN-2006), and it has never been formally reviewed. A thorough CMC review should be conducted for the included drug substance manufacturing information.

b. Due to the previous approval of Oxaliplatin Injection (NDA 21-759), a pharmacology/toxicology consult will not be filed for this NDA. If Pharmacology/Toxicology feedback or confirmation is necessary during the CMC review cycle, this should be obtained as soon as possible.

### **Drug Product**

a. The proposed manufacturing process is conventional for (b) (4) injectable formulations, and compendial excipients are stated in the drug product composition. While the submitted manufacturing and compositional information should be completely assessed, there are no significant (high-risk) triggers in the provided process and compositional information.

b. Due to the injectable nature of the formulation, all sterility assurance information will also be consulted to the Office of Microbiology for review (The request for Micro. Consult is already been sent on 01-MAR-2007). The proposed manufacturing facility is listed below:

Site(s) of Drug Product Manufacturing, Packaging, Labeling, Testing (Release and Stability), and Warehousing and Distribution of Drug Product:

Pharmachemie B.V. Swensweg 5 NL-2031 GA Haarlem The Netherlands

## D. Comments for 74-day Letter:

Stability data analysis and the appropriate SAS transport files should be provided as soon as possible.

Updated primary stability data should be provided as soon as possible.

E. Recommendation for fileability: Fileable

Oxaliplatin Injection

# Fileability Template

	Parameter	Yes	No	Comment
1	On its face, is the section organized adequately?			•
2	Is the section indexed and paginated adequately?			
3	On its face, is the section legible?	V		
4	Are ALL of the facilities (including contract facilities and test laboratories) identified with full street addresses and CFNs?	1		EES have been submitted on 21-FEB-2007
5	Is a statement provided that all facilities are ready for GMP inspection?	1		
6	Has an environmental assessment report or categorical exclusion been provided?	√.		
7	Does the section contain controls for the drug substance?			See DMF 19,559
8	Does the section contain controls for the drug product?			· · · · · · · · · · · · · · · · · · ·
9	Has stability data and analysis been provided to support the requested expiration date?		N	12 M long-term stab. data and 6 M acc. data submitted. Request for <sup>(b)</sup> <sub>(4)</sub> <sup>(b)</sup> exp. dating.
10	Has all information requested during the IND phase, and at the pre- NDA meetings been included?	√		-(4)
11	Have draft container labels been provided?			
12	Has the draft package insert been provided?	$\overline{\mathbf{v}}$		
13	Has a section been provided on pharmaceutical development/ investigational formulations section?	1		
14	Is there a Methods Validation package?	1		· · · · · · · · · · · · · · · · · · ·
15	Is a separate microbiological section included?	V	-	
16	Have all consults been identified and initiated? (bolded items to be handled by ONDQA PM)	V		Microbiology
		√		EES (21-FEB-2007)

# Have all DMF References been identified? Yes ( $\checkmark$ ) ~ No ( )

DMF Number	Holder	Description	LOA
			Included
19559	Sicor de México, S.A. de C.V.	Oxaliplatin	Yes
			(b) (4) Yes
			Yes
			Yes

5

## Oxaliplatin Injection

## **Recommendation for Team Review:**

This NDA includes a significant portion of drug substance manufacturing information, as cross-referenced to a recently-filed Drug Master File (DMF 19559). However, the drug product information is conventional in nature, and the CMC review will be conducted in conjunction with a microbiological assessment/review. The majority of the critical quality attributes for the drug product are microbiological (sterility, endotoxin limits, etc.), and the CMC review for the drug product should be straightforward.

The team review approach is not recommended for this NDA.

Josephine Jee02-MAR-2007CMC ReviewerDate

Ravi Haranpahalli Branch Chief, Branch V

Date

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/ Josephine Jee 4/9/2007 07:45:02 AM CHEMIST

Ravi Harapanhalli 4/16/2007 10:53:04 AM CHEMIST Number: 19,559

DMF No. 19,559

DMF Type: II

(Non-Folable)

Title: Oxaliplatin 1. CHEM REVIEW No. 1

**2. REVIEW DATE: 30-**OCT-2007

### **3. ITEM REVIEWED**

A. IDENTIFICATION USAN:

rINN:

Chemical Name:

(SP-4-2)-( (1 R,2R)-Cyclohexane-1 ,2-diamine- $\kappa$ N,  $\kappa$ N') (ethanedioato (2-)- $\kappa$ O<sup>1</sup>,  $\kappa$ O<sup>2</sup>) platinum

Trade Name:


N/A

CAS Number:

61825-94-3

Oxaliplatin

Other Names: Chemical Name: None provided.



Molecular Weight: 397.3

Molecular Formula: C<sub>8</sub> H<sub>14</sub>N<sub>2</sub>0<sub>4</sub>Pt

PHONE: N/A

### 4. DOCUMENTS

Type of Document	Date of Document	<u>Location</u>
Original	07-AUG-2006	Vol. 1.1, Vol., 1.2, Vol. 1.3

## 5. NAME & ADDRESS OF DMF HOLDER REPRESENTATIVE(S):

Name (Holder): Address:	Sicor de México, S.A. de C.V. Av. San Rafael 35 Parque Industrial Lerma CP 52000 Lerma, Estado de Mexico Mexico
Responsible Agent:	Jovita Trinidad, Regulatory Manager
Name (Agent):	Plantex USA, Inc 2 University Plaza, Suite 305 Hackensack, New Jersey 07601 Tel: (201) 343-4141 Fax: (201) 343-3833

REPRESENTATIVE or U.S. AGENT: NAME: N/A

CONTACT PERSON NAME: Carolyn Leitgeb Administrative Assistant – Customer Service ADDRESS: Plantex USA, Inc 2 University Plaza, Suite 305 Hackensack, New Jersey 07601

6. DMF REFERENCED FOR:	
NDA:	22-160
PRIMARY DMF:	Yes
Applicant Name:	Teva Parenteral Medicines, Inc.
LOA DATE:	14-AUG-2006

DRUG PRODUCT NAME:	Oxaliplatin
DOSAGE FORM:	Injection
CODE:	
STRENGTH:	5 mg/mL (50 mg/10 mL and 100 mg/ 20 mL)
ROUTE OF ADMINISTRATION:	Oral

7. SUPPORTING DOCUMENTS: NDA 22-160

#### 8. CURRENT STATUS OF DMF:

DATE OF LAST UPDATE OF DMF: 07-AUG-2006 (Original submission) Date of most recent List of Companies for which LOA's Have Been Provided: August 7, 2007

#### 9. CONSULTS: None

10. COMMENTS: DMF 19,559 has not provided all required information; see pp 23-24 of this review for comments.

#### 11. CONCLUSIONS: Inadequate.

11/5/07 VIL hine/see

Review Chemist, CMC Branch V (Pre-Marketing) Division of Pre-Market Assessment III & Manufacturing Science, ONDQA

115/07

Ravi Harapanhalli, Ph. D. (*l*) Chief, CMC Branch V (Pre-Marketing) Division of Pre-Market Assessment III & Manufacturing Science, ONDQA.

cc: Orig. DMF 19,559 DDOP DMF File DDOP/J.Jee/30-OCT-2007 DDOP/R.Harapanhalli DDOP/D.Pease Doc: DMF 19559 Oxaliplatin.doc

20 Page(s) has been Withheld in Full immediately following this page as B4 (CCI/TS)

←(s0P+&k4S+&17.27c66F 20-FEB-2009 Page 1 of 4 FDA CDER EES

ESTABLISHMENT EVALUATION REQUEST

DETAIL REPORT

Application:	NDA 22160/000	Action Goal:	
Stamp:	09-FEB-2007	District Goal:	01-JAN-2009
Regulatory D	ue: 02-MAR-2009	Brand Name:	OXALIPLATIN INJECTION
Applicant:	TEVA PARENTERAL	Estab. Name:	
19 HUGHES		Generic Name:	OXALIPLATIN INJECTION
IRVINE, CA 92618			
Priority:	5S	Dosage Form:	(INJECTION)
Org Code:	150	Strength:	5.0 MG/ML

Application Comment: APPLICATION WAS RESUBMITTED ON 2-SEPTEMBER-2008, SO ESTABLISHMENTS ARE BEING RESUBMITTED. (on 09-DEC-2008 by D. MESMER (HFD-800) 301-796-4023) PHARMACHEMIE PERFORMS THE FOLLOWING: DRUG PRODUCT MANUFACTURING, PACKAGING, LABELING, TESTING (RELEASE AND STABILITY), AND

> WAREHOUSING AND DISTRIBUTION OF DRUG PRODUCT. PLEASE CHECK FOR FACILITY ADEQUACY FOR THESE FUNCTIONS.

SICOR DE MEXICO IS THE MANUFACTURER OF OXALIPLATIN DRUG SUBSTANCE. CHECK FOR ADEQUACY. (on 21-FEB-2007 by J. JEE () 301-796-1375)

FDA Contacts: D. MESMER		MER (H	(HFD-800)		301-796-4023 , Project Manager		
	J. JEE			301-796-1375	, Review Chemist		
	H. SAR	KER (H	FD-150)	301-796-1747	, Team Leader		
<b></b>							
Overall Recommendat	ion:	ACCEPTABLE	on 05-FEB-200	9by S. ADAMS (HF	D-325)301-796-3193		
×		ACCEPTABLE	on 27-NOV-200	)7by S. ADAMS (HF	D-325)301-796-3193		
f <sup>2</sup>	<b>_</b>						
	_						
Establishment:	CFN	9611517	FEI	3002807910			

PHARMACHEMIE BV

SWENSWEG 5

HAARLEM, , NL

DM<sup>-</sup> No: 8786

AADA:

Responsibilities: FINISHED DOSAGE MANUFACTURER

Profile: (b) (4) OAI Status: NONE

Estab. Comment: APPLICATION WAS RESUBMITTED ON 2-SEPTEMBER-2008, SO ESTABLISHMENTS ARE BEING RESUBMITTED. PHARMACHEMIE PERFORMS THE FOLLOWING: DRUG PRODUCT MANUFACTURING, PACKAGING, LABELING, TESTING (ANALYTICAL, RELEASE AND STABILITY), AND WAREHOUSING AND DISTRIBUTION OF DRUG PRODUCT. PLEASE CHECK FOR FACILITY ADEQUACY FOR THESE FUNCTIONS. (on 09-DEC-2008 by D. MESMER (HFD-800)

301-796-4023)

Milestone Name	Date	Туре	Insp. Date	Decision & Reason	Creator
			<b></b>		
SUBMITTED TO OC	21-FEB-2007				JEE
MITTED TO DO	22-FEB-2007	GMP			ADAMSS
ASSIGNED INSPECTION T	23-FEB-2007	GMP			ADAMSS
INSPECTION SCHEDULED	14 <b>-</b> JUN-2007.		05-JUL-2007		IRIVERA
INSPECTION PERFORMED	05-JUL-2007		05-JUL-2007		ADAMSS

s.

FDA CDER EES

Page 2 of 4

BRUCE.MCCUL

### ESTABLISHMENT EVALUATION REQUEST

DETAIL REPORT

INSPECTION PERFORMED 05-JUL-2007 05-JUL-2007 This was a drug CGMP and pre-approval (PDUFA) EI of a (b) (4) manufacturer, initiated by

CDER/OC/DMPQ/IPCB. FACTS assignment ID: 3800173.

CGMP coverage was a full-option inspection, covering the Quality, Facilities & Equipment, Production, and Laboratory Systems. Pre-Approval coverage included: NDA 022-160 Oxaliplatin Injection, 5 mg/mL; (b) (4)

(b) (4)

The previous inspection (5/3-7/04) covered	Profile Classes	(b)(4) and was
classified OAI. That inspection revealed	CGMP deficiencies asso	ociated with: (b)(4)

At the beginning of the current inspection, we identified ourselves to Jan P.P. Moors, Vice-President, Quality Assurance. The current inspection revealed corrections to the previous observations. However, the current inspection revealed other CGMP deficiencies

regarding	<sup>(b)(4)</sup> includi	ing:			
-				(b) (4)	
DO RECOMMENDATION	27-NOV-2007			ACCEPTABLE	ADAMSS
				ADEQUATE FIRM RESPONSE	
FIRM PROVIDED ADDITIO	NAL CORRECTIVE A	ACTIONS AS	REQUESTEI	BY CDER/OFFICE OF COMPL	IANCE.
OC RECOMMENDATION	27-NOV-2007			ACCEPTABLE	ADAMSS
				FIRM RESPONSE TO DEFIC.	ADEQUA
SUBMITTED TO OC	09-DEC-2008				MESMERD
SUBMITTED TO DO	15-DEC-2008 GM	MP			ADAMSS
ASSIGNED INSPECTION T	10-JAN-2009 GM	MP			ADAMSS
DO RECOMMENDATION	05-FEB-2009			ACCEPTABLE	ADAMSS
				BASED ON FILE REVIEW	
AC GMP EI 7/2007					
OC RECOMMENDATION	05-FEB-2009			ACCEPTABLE	ADAMSS
				DISTRICT RECOMMENDATION	
Establishment: CFN	9616073		FEI 3	3002808102	
SIC	OR DE MEXICO S.A	A. DE C.V.			

AVENIDA SAN RAFAEL 35

(b) (4)

#### ESTABLISHMENT EVALUATION REQUEST

#### DETAIL REPORT

LERMA, EDO. DE. MEXICO, MX

DMF No: 19559 AADA:

Responsibilities: DRUG SUBSTANCE MANUFACTURER

Profile:	(b) (4)	OAI	Status:	NONE
Prolite:		0A1	Status:	NONE

Estab. Comment: APPLICATION WAS RESUBMITTED ON 2-SEPTEMBER-2008, SO ESTABLISHMENTS ARE BEING RESUBMITTED. SICOR DE MEXICO IS THE MANUFACTURER OF OXALIPLATIN DRUG SUBSTANCE. CHECK FOR ADEQUACY. (on 09-DEC-2008 by D. MESMER (HFD-800) 301-796-

4023)

estone Name	Date	Туре	Insp. Date	Decision & Reason	Creator
<b></b>				<b>_</b>	
SUBMITTED TO OC	21-FEB-2007				JEE
SUBMITTED TO DO	22-FEB-2007	GMP			ADAMSS
ASSIGNED INSPECTION	T 23-FEB-2007	GMP			ADAMSS
INSPECTION PERFORMED	19-APR-2007		19-APR-2007		VLADA.MATUS

This pre-approval inspection of an API manufacturer was initiated in response to FACTS Assignment # 3960790, Operation ID # 3171828 and an assignment from International District Pre-Approval Manager requesting coverage of APIs used in manufacturing of

Oxaliplatin Injection, 5 mg/ml, NDA # 22160/000 (b)(4) This inspection was conducted in accordance with C.P. 7356.002F, C.P. 7346.832 and C.P. 7352.832. previous inspection of the firm, dated 1/12-22/04, was classified VAI. This inspection revealed the following cGMP deficiencies, which were documented on the Form FDA-483: Corrections implemented by the firm in response to these deficiencies were evaluated during the current inspection.

The current inspection revealed that the firm continues as a manufacturer of API's cributed worldwide. Quality, Laboratory Control, Facilities and Equipment and Production Systems were evaluated. The following deficiencies were documented on the Form FDA-483 issued to the firm's management at the conclusion of this inspection:

(b) (4)

incomplete investigation into customer complaint, no assurance of reproducibility of HPLC instrument used in Oxaliplatin API assay testing and no record of standard weights used during related substance analysis of Oxaliplatin <sup>(b) (4)</sup> <sup>(b) (4)</sup>. The firm's management promised corrections. There were no samples collected and no refusals were encountered.

INSPECTION SCHEDULED	21-MAY-2007	20-APR-2007		IRIVERA
DO RECOMMENDATION	15-AUG-2007		ACCEPTABLE	ADAMSS
			INSPECTION	
<pre></pre>	16-AUG-2007		ACCEPTABLE	ADAMSS
			DISTRICT RECOMMENDATION	
SUBMITTED TO OC	09-DEC-2008			MESMERD
OC RECOMMENDATION	15-DEC-2008		ACCEPTABLE	ADAMSS

\_\_\_\_\_

## ESTABLISHMENT EVALUATION REQUEST

DETAIL REPORT

BASED ON PROFILE